Psoriasis immunometabolism: progress on metabolic biomarkers and targeted therapy
Psoriasis is a common inflammatory disease that affects mainly the skin. However, the moderate to severe forms have been associated with several comorbidities, such as psoriatic arthritis, Crohn’s disease, metabolic syndrome and cardiovascular disease. Keratinocytes and T helper cells are the domina...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2023.1201912/full |
| _version_ | 1797800178983370752 |
|---|---|
| author | Evangelia Sarandi Evangelia Sarandi Sabine Krueger-Krasagakis Dimitris Tsoukalas Dimitris Tsoukalas Polytimi Sidiropoulou Polytimi Sidiropoulou George Evangelou Maria Sifaki Gottfried Rudofsky Nikolaos Drakoulis Aristidis Tsatsakis |
| author_facet | Evangelia Sarandi Evangelia Sarandi Sabine Krueger-Krasagakis Dimitris Tsoukalas Dimitris Tsoukalas Polytimi Sidiropoulou Polytimi Sidiropoulou George Evangelou Maria Sifaki Gottfried Rudofsky Nikolaos Drakoulis Aristidis Tsatsakis |
| author_sort | Evangelia Sarandi |
| collection | DOAJ |
| description | Psoriasis is a common inflammatory disease that affects mainly the skin. However, the moderate to severe forms have been associated with several comorbidities, such as psoriatic arthritis, Crohn’s disease, metabolic syndrome and cardiovascular disease. Keratinocytes and T helper cells are the dominant cell types involved in psoriasis development via a complex crosstalk between epithelial cells, peripheral immune cells and immune cells residing in the skin. Immunometabolism has emerged as a potent mechanism elucidating the aetiopathogenesis of psoriasis, offering novel specific targets to diagnose and treat psoriasis early. The present article discusses the metabolic reprogramming of activated T cells, tissue-resident memory T cells and keratinocytes in psoriatic skin, presenting associated metabolic biomarkers and therapeutic targets. In psoriatic phenotype, keratinocytes and activated T cells are glycolysis dependent and are characterized by disruptions in the TCA cycle, the amino acid metabolism and the fatty acid metabolism. Upregulation of the mammalian target of rapamycin (mTOR) results in hyperproliferation and cytokine secretion by immune cells and keratinocytes. Metabolic reprogramming through the inhibition of affected metabolic pathways and the dietary restoration of metabolic imbalances may thus present a potent therapeutic opportunity to achieve long-term management of psoriasis and improved quality of life with minimum adverse effects. |
| first_indexed | 2024-03-13T04:31:13Z |
| format | Article |
| id | doaj.art-a69e333fb04e4252b2d30f1ad2637f2d |
| institution | Directory Open Access Journal |
| issn | 2296-889X |
| language | English |
| last_indexed | 2024-03-13T04:31:13Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj.art-a69e333fb04e4252b2d30f1ad2637f2d2023-06-19T14:23:16ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2023-06-011010.3389/fmolb.2023.12019121201912Psoriasis immunometabolism: progress on metabolic biomarkers and targeted therapyEvangelia Sarandi0Evangelia Sarandi1Sabine Krueger-Krasagakis2Dimitris Tsoukalas3Dimitris Tsoukalas4Polytimi Sidiropoulou5Polytimi Sidiropoulou6George Evangelou7Maria Sifaki8Gottfried Rudofsky9Nikolaos Drakoulis10Aristidis Tsatsakis11Laboratory of Toxicology and Forensic Sciences, Medical School, University of Crete, Heraklion, GreeceMetabolomic Medicine, Health Clinics for Autoimmune and Chronic Diseases, Athens, GreeceDermatology Department, University Hospital of Heraklion, Heraklion, GreeceMetabolomic Medicine, Health Clinics for Autoimmune and Chronic Diseases, Athens, GreeceEuropean Institute of Molecular Medicine, Rome, Italy1st Department of Dermatology-Venereology, Faculty of Medicine, “A. Sygros” Hospital, National and Kapodistrian University of Athens, Athens, GreeceResearch Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, GreeceDermatology Department, University Hospital of Heraklion, Heraklion, GreeceResearch Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, GreeceClinic of Endocrinology and Metabolic Disorders, Cantonal Hospital Olten, Olten, SwitzerlandResearch Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, GreeceLaboratory of Toxicology and Forensic Sciences, Medical School, University of Crete, Heraklion, GreecePsoriasis is a common inflammatory disease that affects mainly the skin. However, the moderate to severe forms have been associated with several comorbidities, such as psoriatic arthritis, Crohn’s disease, metabolic syndrome and cardiovascular disease. Keratinocytes and T helper cells are the dominant cell types involved in psoriasis development via a complex crosstalk between epithelial cells, peripheral immune cells and immune cells residing in the skin. Immunometabolism has emerged as a potent mechanism elucidating the aetiopathogenesis of psoriasis, offering novel specific targets to diagnose and treat psoriasis early. The present article discusses the metabolic reprogramming of activated T cells, tissue-resident memory T cells and keratinocytes in psoriatic skin, presenting associated metabolic biomarkers and therapeutic targets. In psoriatic phenotype, keratinocytes and activated T cells are glycolysis dependent and are characterized by disruptions in the TCA cycle, the amino acid metabolism and the fatty acid metabolism. Upregulation of the mammalian target of rapamycin (mTOR) results in hyperproliferation and cytokine secretion by immune cells and keratinocytes. Metabolic reprogramming through the inhibition of affected metabolic pathways and the dietary restoration of metabolic imbalances may thus present a potent therapeutic opportunity to achieve long-term management of psoriasis and improved quality of life with minimum adverse effects.https://www.frontiersin.org/articles/10.3389/fmolb.2023.1201912/fullpsoriasisT cellkeratinocyteglycolysislipid metabolismTCA |
| spellingShingle | Evangelia Sarandi Evangelia Sarandi Sabine Krueger-Krasagakis Dimitris Tsoukalas Dimitris Tsoukalas Polytimi Sidiropoulou Polytimi Sidiropoulou George Evangelou Maria Sifaki Gottfried Rudofsky Nikolaos Drakoulis Aristidis Tsatsakis Psoriasis immunometabolism: progress on metabolic biomarkers and targeted therapy Frontiers in Molecular Biosciences psoriasis T cell keratinocyte glycolysis lipid metabolism TCA |
| title | Psoriasis immunometabolism: progress on metabolic biomarkers and targeted therapy |
| title_full | Psoriasis immunometabolism: progress on metabolic biomarkers and targeted therapy |
| title_fullStr | Psoriasis immunometabolism: progress on metabolic biomarkers and targeted therapy |
| title_full_unstemmed | Psoriasis immunometabolism: progress on metabolic biomarkers and targeted therapy |
| title_short | Psoriasis immunometabolism: progress on metabolic biomarkers and targeted therapy |
| title_sort | psoriasis immunometabolism progress on metabolic biomarkers and targeted therapy |
| topic | psoriasis T cell keratinocyte glycolysis lipid metabolism TCA |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2023.1201912/full |
| work_keys_str_mv | AT evangeliasarandi psoriasisimmunometabolismprogressonmetabolicbiomarkersandtargetedtherapy AT evangeliasarandi psoriasisimmunometabolismprogressonmetabolicbiomarkersandtargetedtherapy AT sabinekruegerkrasagakis psoriasisimmunometabolismprogressonmetabolicbiomarkersandtargetedtherapy AT dimitristsoukalas psoriasisimmunometabolismprogressonmetabolicbiomarkersandtargetedtherapy AT dimitristsoukalas psoriasisimmunometabolismprogressonmetabolicbiomarkersandtargetedtherapy AT polytimisidiropoulou psoriasisimmunometabolismprogressonmetabolicbiomarkersandtargetedtherapy AT polytimisidiropoulou psoriasisimmunometabolismprogressonmetabolicbiomarkersandtargetedtherapy AT georgeevangelou psoriasisimmunometabolismprogressonmetabolicbiomarkersandtargetedtherapy AT mariasifaki psoriasisimmunometabolismprogressonmetabolicbiomarkersandtargetedtherapy AT gottfriedrudofsky psoriasisimmunometabolismprogressonmetabolicbiomarkersandtargetedtherapy AT nikolaosdrakoulis psoriasisimmunometabolismprogressonmetabolicbiomarkersandtargetedtherapy AT aristidistsatsakis psoriasisimmunometabolismprogressonmetabolicbiomarkersandtargetedtherapy |